SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CRL

Charles River Laboratories International, Inc. (New York Stock Exchange:CRL)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$314.32-$13.61 (-4.15%)
 
Market cap
$15.1B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 23, 2000
Website
Market Cap$15.06B+84.4%
Revenue (ttm)$3.98B-1.2%
Net Income$40.19M+148.1%
EPS$0.91+158.3%
Shares Out47.92M
PE Ratio308.16
Forward PE24.32
Dividendn/a
Ex-Dividend Daten/a
Volume1,154,114
Open$324.71
Previous Close$327.93
Day's Range$310.52 - $326.62
52-Week Range$146.20 - $379.63
Beta1.34
AnalystsBuy
Price Target$313.67(-0.21%)
Earnings DateFeb 17, 2027

About CRL

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Address
251 Ballardvale Street, Wilmington, MA, 01887, US
Market Cap
15.06 billion
Employees
19,000
Industrial Classification
Medical - Diagnostics & Research

Charles River Laboratories International, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
23rd Percentile Overall Score
CRL InsiderScore:56 / 99

Charles River Laboratories International, Inc. scored higher than 23% of companies evaluated by InsiderBuying, and ranked 43rd out of 56 stocks in the healthcare sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Charles River Laboratories International, Inc. bought $3.0K of stock across 1 purchase in the last 90 days, the largest of them $3.0K.

Stake Increase

The average purchase added about 0% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$31.47M
Bought
$2.97K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
9 Buy1 Hold0 SellAvg target $289.75 (-7.8%)

10 firms rating CRL in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From CRL’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-4.15%
5 Days
-5.93%
1 Month
-7.46%
6 Months
+96.08%
1 Year
+84.42%

$CRL stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of CRL by members of U.S. Congress

Julie JohnsonHouse / DPurchase$1.00K – $15.00KJan 15, 2025
Donna ShalalaHouseSale$1.00K – $15.00KJun 24, 2019

Recently reported changes in CRL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CRL's directors and management

Net Shares Purchased by Insiders−80k−40k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CRL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CRL Revenue by Segment or Geography

$982.73MTotal
DSA$596.32M60.68%
RMS$207.53M21.12%
Manufacturing$178.88M18.20%

As of: Q3 2026 (Sep 26, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CRL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CRL from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CRL

VOOVanguard S&P 500 ETF$456.04M
VTIVanguard Morningstar Total Stock Market ETF$430.21M
VBVanguard Morningstar Small-Cap ETF$384.65M
VBRVanguard Morningstar Small-Cap Value ETF$250.05M
RSPInvesco S&P 500 Equal Weight ETF$240.93M
IVViShares Core S&P 500 ETF$210.94M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CRL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
55.64
Analyst Ratings
32% of score
79
News & Sentiment
20% of score
72

News check: Strong YoY stock performance, analyst price target maintained, geographic expansion, and business partnerships indicate positive momentum despite valuation questions.

Recent Insider Activity

Buys
1
Sells
11
Buy Value
$2.97K
Distinct Buyers
1

Insider Score Trend Over Time

+55.6 since Sep 24
0255075100Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 32.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 70.3Oct 5 — Insider Score 70.4Oct 6 — Insider Score 69.3Oct 7 — Insider Score 69.1Oct 8 — Insider Score 68.8Oct 9 — Insider Score 68.7Oct 10 — Insider Score 68.2Oct 11 — Insider Score 69.2Oct 12 — Insider Score 69.3Oct 13 — Insider Score 68.9Oct 14 — Insider Score 68.5Oct 15 — Insider Score 68.6Oct 16 — Insider Score 68.1Oct 17 — Insider Score 68.1Oct 18 — Insider Score 68.4Oct 19 — Insider Score 68.3Oct 20 — Insider Score 68.3Oct 21 — Insider Score 68.1Oct 22 — Insider Score 68.2Oct 23 — Insider Score 68.2Oct 24 — Insider Score 68.2Oct 25 — Insider Score 67.8Oct 26 — Insider Score 67.8Oct 27 — Insider Score 68.0Oct 28 — Insider Score 67.8Oct 29 — Insider Score 67.7Oct 30 — Insider Score 66.5Oct 31 — Insider Score 66.0Nov 1 — Insider Score 66.3Nov 2 — Insider Score 66.4Nov 3 — Insider Score 65.7Nov 4 — Insider Score 65.2Nov 5 — Insider Score 64.6Nov 6 — Insider Score 63.7Nov 7 — Insider Score 63.1Nov 8 — Insider Score 64.0Nov 9 — Insider Score 64.6Nov 10 — Insider Score 63.1Nov 11 — Insider Score 62.2Nov 12 — Insider Score 62.4Nov 13 — Insider Score 61.2Nov 14 — Insider Score 60.5Nov 15 — Insider Score 60.9Nov 16 — Insider Score 60.7Nov 17 — Insider Score 60.6Nov 18 — Insider Score 59.6Nov 19 — Insider Score 58.6Nov 20 — Insider Score 55.6Nov 21 — Insider Score 55.0Nov 22 — Insider Score 55.6Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

OAKLOakmark U.S. Concentrated ETF4.28%
FCUSPinnacle Focused Opportunities ETF3.38%
EPSBHarbor SMID Cap Core ETF (EPSB)3.28%
SAMMStrategas Macro Momentum ETF3.20%
FMTMMarketDesk Focused U.S. Momentum ETF3.16%
IVDGInvesco Focused Discovery Growth ETF2.88%
EPAIHarbor ETF Trust - Harbor AI Inflection Strategy ETF2.52%
EPSVHarbor SMID Cap Value ETF (EPSV)2.48%
QMOMAlpha Architect U.S. Quantitative Momentum ETF2.43%
PTHInvesco Dorsey Wright Healthcare Momentum ETF2.37%
EPMVHarbor Mid Cap Value ETF (EPMV)2.17%
SAEFSchwab Ariel ESG ETF1.90%

Weight is the stock’s share of each fund’s holdings.